Tirzepatide is an FDA-approved drug — sold as Mounjaro (diabetes) and Zepbound (weight management) by Eli Lilly. Yet the brand-name cost of $1,000+ per month puts it out of reach for most patients without insurance coverage, and a parallel market of compounded tirzepatide has emerged at $229–349/month through telehealth platforms and 503A compounding pharmacies (GLP-1 After Denial, 2026). That price gap has created a large, partially regulated market where quality and legality vary significantly depending on where you source.
The 72-week SURMOUNT-5 head-to-head trial against semaglutide — showing 20.2% weight loss vs. semaglutide's 13.7% (NEJM, 2025) — has made tirzepatide the most sought-after weight management compound of 2025–2026. Understanding the legal access routes before you start is essential.
Key Takeaways
- —Tirzepatide (Mounjaro/Zepbound) is FDA-approved — access routes are brand-name with insurance, compounded via 503A pharmacy with prescription, or through programmes like LillyDirect ($299–449/month).
- —503A compounding is legal while tirzepatide remains on the FDA shortage list; the FDA has sent thousands of warning letters to platforms making misleading advertising claims about compounded GLP-1s.
- —The active pharmaceutical ingredient in any compounded tirzepatide must come from an FDA-registered manufacturer — this is the primary quality verification point.
- —Compare tirzepatide vs. semaglutide side-by-side using the Next Pep comparison tool before choosing a protocol.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first approved peptide to activate both incretin pathways simultaneously. Brand-name Zepbound (the weight management indication) carries a list price of approximately $1,060/month for the maintenance dose, though out-of-pocket costs vary significantly with insurance coverage (Empower Pharmacy, 2025). Without coverage or manufacturer coupons, the cost is prohibitive for sustained use.
The manufacturer's LillyDirect programme offers self-pay pricing at $299–449/month, but with geographic restrictions and ongoing availability issues. This gap between clinical demand and accessible pricing is what has made 503A compounded tirzepatide so significant.
There are three legal pathways, each with different quality implications.
1. Brand-name Mounjaro or Zepbound through a physician. This is the only fully FDA-approved route. The product is manufactured under GMP standards, has full regulatory traceability, and carries the clinical trial data. Insurance coverage, prior authorisation requirements, and cost are the barriers.
2. 503A compounding pharmacy with a prescription. While tirzepatide appears on the FDA drug shortage list, licensed 503A compounding pharmacies can legally prepare it for individual patients with a valid prescription. The 503A framework requires sterile compounding under USP <797> standards, but does not require the same GMP manufacturing controls as brand-name production. The active pharmaceutical ingredient must come from an FDA-registered supplier — pharmacies sourcing API from non-registered overseas manufacturers are operating outside compliance (FDA guidance, 2026).
3. 503B outsourcing facilities. These operate under stricter GMP-adjacent standards than 503A pharmacies and can produce larger batches. Some 503B facilities have been involved in the GLP-1 compounding market. They face more intense FDA oversight and periodic inspections.
Compounded tirzepatide quality varies between pharmacies. These are the checks that matter.
API source verification. Ask the pharmacy specifically whether their tirzepatide API comes from an FDA-registered manufacturer. A PCAB-accredited pharmacy will answer this directly. If the answer is vague or references overseas suppliers, that's a meaningful risk flag.
Batch-specific COA. The pharmacy should provide a certificate of analysis for the specific batch dispensed — including concentration confirmation (typically 2.5 mg/0.5 mL or 5 mg/0.5 mL), sterility testing, and endotoxin assay. Tirzepatide is a subcutaneous injectable, so sterility and endotoxin burden matter significantly.
PCAB accreditation. Not all 503A pharmacies have Pharmacy Compounding Accreditation Board accreditation. PCAB-accredited pharmacies have passed independent facility audits and quality system reviews. It's the clearest available signal of a pharmacy's quality commitment.
Beyond-use dating. Compounded tirzepatide injectables should carry a specific beyond-use date, not just "refrigerate and use within X weeks." USP-based beyond-use dating for sterile injectables accounts for the specific formulation, container closure, and storage conditions.
Imported API from non-FDA-registered facilities. This is the single largest quality risk in the compounded GLP-1 market. Some operations are sourcing tirzepatide API from overseas chemical manufacturers without FDA registration — meaning the active ingredient hasn't been inspected against US pharmaceutical standards. The CT Attorney General sued one GLP-1 distributor in 2025 specifically over undisclosed overseas API sourcing.
Bioequivalence claims. Platforms that explicitly claim their compounded tirzepatide is "equivalent to Zepbound" or "the same active ingredient" are making claims the FDA has explicitly prohibited via warning letters. The chemistry is slightly different (tirzepatide base vs. tirzepatide salt). Whether this affects clinical outcomes is unknown — and that uncertainty is what the FDA warning addresses.
No physician involvement. Legitimate telehealth platforms require a synchronous or asynchronous clinical evaluation before prescribing. Platforms that issue prescriptions via questionnaire without any clinician review of labs or history aren't providing medical oversight — they're providing access, which isn't the same thing.
Missing beyond-use date. Any injectable that doesn't carry a specific beyond-use date on the label should be returned.
Before selecting a telehealth provider or pharmacy, understanding what tirzepatide is — and how it differs from semaglutide — makes the clinical conversation significantly more productive. The tirzepatide research profile on Next Pep covers the dual GIP/GLP-1 mechanism, the SURMOUNT-5 72-week head-to-head data, and pharmacokinetics in one place. The peptide library gives you the full tirzepatide and semaglutide profiles side-by-side in structured, citation-backed format.
If you're deciding between tirzepatide and semaglutide, the comparison tool puts them side by side so you can evaluate the mechanism and evidence differences before walking into a consultation. For protocol planning once you have a prescription, the dosing calculator handles the maths for any injectable peptide — enter your vial concentration and target dose to get exact draw volume and syringe units. Next Pep is the independent, non-commercial research reference — no referral fee, no platform stake, just the published data.
Compounded tirzepatide uses tirzepatide base, while Zepbound uses tirzepatide citrate (a salt form). The core peptide sequence is identical, but the formulations are chemically distinct. The FDA has explicitly prohibited advertising that describes them as equivalent. Clinical equivalence hasn't been studied head-to-head. For most patients the practical difference may be negligible — but it's not established, and any platform claiming bioequivalence is misrepresenting the current evidence.
Yes — while tirzepatide remains on the FDA drug shortage list, 503A compounding pharmacies with a licensed physician's prescription can legally compound and dispense it. The shortage list status has been subject to ongoing review; if tirzepatide is removed from the shortage list (as semaglutide was in early 2025), compounding legality would change. Check current shortage list status at the FDA website before initiating a protocol.
At minimum: HbA1c and fasting glucose (metabolic baseline), lipid panel, comprehensive metabolic panel (kidney and liver function), thyroid stimulating hormone (TSH), and if relevant, a personal or family history screen for medullary thyroid carcinoma (a contraindication for GLP-1 agonists). Providers who start patients on tirzepatide without any baseline metabolic labs are not following evidence-based prescribing practice.
The SURMOUNT-5 72-week head-to-head RCT showed tirzepatide achieving 20.2% weight loss vs. semaglutide's 13.7% — a statistically significant difference. However, individual responses vary, side effect profiles differ slightly, and cost/access considerations differ by insurance and geography. The Next Pep comparison tool lets you evaluate both compounds against mechanism, dosing, and pharmacokinetic data before your clinical consultation.
This article is for informational purposes only. Tirzepatide (Mounjaro/Zepbound) is an FDA-approved prescription medication. Compounded tirzepatide requires a licensed physician's prescription. Consult a qualified healthcare provider before starting any GLP-1 protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.